The impact of quasispecies dynamics on the use of therapeutics

Trends in Microbiology

Volumn 20, Issue 12, 2012, Pages 595-603

  Perales, Celia ^a,b   Iranzo, Jaime ^c   Manrubia, Susanna C ^c   Domingo, Esteban ^a,b,c  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO DE ASTROBIOLOGÍA CSIC INTA   (Spain)

Author keywords

Combination therapy; Lethal defection; Lethal mutagenesis; Quasispecies models; Sequential therapy

Indexed keywords

ANTIVIRUS AGENT; DOUBLE STRANDED RNA; FLUOROURACIL; SINGLE STRANDED RNA;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; GENE DOSAGE; GENE SEQUENCE; GENETIC COMPLEMENTATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGENY; QUASISPECIES; REVIEW; SPECIES DIFFERENCE; SPECIES EXTINCTION; VIRUS GENOME; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENETIC VARIATION; HUMANS; MODELS, THEORETICAL; MUTATION; RECOMBINATION, GENETIC; SELECTION, GENETIC; VIRUS DISEASES; VIRUSES;

EID: 84869506027     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.08.010     Document Type: Review

References (80)

1. Eigen M. Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften 1971, 58:465-523.
2. Eigen M. Steps Towards Life 1992, Oxford University Press.
3. Eigen M., Schuster P. The Hypercycle. A Principle of Natural Self-organization 1979, Springer.
4. Domingo E., et al. Nucleotide sequence heterogeneity of an RNA phage population. Cell 1978, 13:735-744.
5. Domingo E. Quasispecies: Concepts and Implications for Virology (Current Topics in Microbiology and Immunology, Vol. 299) 2006, Springer.
6. Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010, 6:e1001005.
7. Domingo E., et al. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76:159-216.
8. Batschelet E., et al. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1976, 1:27-32.
9. Drake J.W., Holland J.J. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13910-13913.
10. Sanjuan R., et al. Viral mutation rates. J. Virol. 2010, 84:9733-9748.
11. Steinhauer D.A., et al. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 1992, 122:281-288.
12. Ferrer-Orta C., et al. A comparison of viral RNA-dependent RNA polymerases. Curr. Opin. Struct. Biol. 2006, 16:27-34.
13. Friedberg E.C., et al. DNA Repair and Mutagenesis 2006, American Society for Microbiology.
14. Vandenbroucke I., et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011, 51:167-177.
15. Macalalad A.R., et al. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput. Biol. 2012, 8:e1002417.
16. Hinkley T., et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat. Genet. 2011, 43:487-489.
17. Lauring A.S., Andino R. Exploring the fitness landscape of an RNA virus by using a universal barcode microarray. J. Virol. 2011, 85:3780-3791.
18. Bonhoeffer S., et al. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6971-6976.
19. Müller V., Bonhoeffer S. Intra-host dynamics and evolution of HIV infections. Origin and Evolution of Viruses 2008, 2nd edn:279-302. Elsevier.
20. Domingo E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 1989, 33:93-133.
21. Domingo E., Holland J.J. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet. Eng. (N. Y.) 1992, 14:13-31.
22. Taboga O., et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 1997, 71:2606-2614.
23. Zubkova I., et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009, 27:2594-2602.
24. Quer J., et al. The impact of rapid evolution of hepatitis viruses. Origin and Evolution of Viruses 2008, 2nd edn:303-350. Elsevier.
25. Briones C., Domingo E. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev. 2008, 10:93-109.
26. Wilke C.O. Quasispecies theory in the context of population genetics. BMC Evol. Biol. 2005, 5:44.
27. Torella J.P., et al. Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol. 2010, 6:e1000796.
28. Fitzgerald J.B., et al. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2006, 2:458-466.
29. Iranzo J., et al. Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16008-16013.
30. Ho D.D. Time to hit HIV, early and hard. N. Engl. J. Med. 1995, 333:450-451.
31. Le Moing V., et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002, 16:21-29.
32. Nijhuis M., et al. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 2009, 189:299-320.
33. Pol S., et al. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J. Hepatol. 1999, 31:1-7.
34. Van Vaerenbergh K., et al. Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res. Hum. Retroviruses 2002, 18:419-426.
35. Li M.J., et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12:900-909.
36. Seiler P., et al. Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J. Virol. 2000, 74:5896-5901.
37. Webster R.G., et al. Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus. J. Antimicrob. Chemother. 1986, 18:157-164.
38. von Kleist M., et al. HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS ONE 2011, 6:e18204.
39. Garbelli A., et al. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr. Med. Chem. 2011, 18:3015-3027.
40. Geller R., et al. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007, 21:195-205.
41. Hopkins S., et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 2010, 54:660-672.
42. Kumar N., et al. Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication. J. Virol. 2011, 85:2818-2827.
43. Biebricher C.K., Eigen M. The error threshold. Virus Res. 2005, 107:117-127.
44. Swetina J., Schuster P. Self-replication with errors. A model for polynucleotide replication. Biophys. Chem. 1982, 16:329-345.
45. Holland J.J., et al. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64:3960-3962.
46. Lee C.H., et al. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J. Virol. 1997, 71:3636-3640.
47. Loeb L.A., Mullins J.I. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res. Hum. Retroviruses 2000, 13:1-3.
48. Crotty S., et al. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6895-6900.
49. Severson W.E., et al. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 2003, 77:481-488.
50. Sierra S., et al. Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J. Virol. 2000, 74:8316-8323.
51. Sierra M., et al. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 2007, 81:2012-2024.
52. Airaksinen A., et al. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003, 311:339-349.
53. Pariente N., et al. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 2003, 77:7131-7138.
54. Pariente N., et al. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 2001, 75:9723-9730.
55. Tapia N., et al. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 2005, 338:1-8.
56. Grande-Pérez A., et al. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4448-4452.
57. Grande-Pérez A., et al. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12938-12943.
58. Loeb L.A., et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1492-1497.
59. Domingo E. Virus entry into error catastrophe as a new antiviral strategy. Virus Res. 2005, 107:115-228.
60. Anderson J.P., et al. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 2004, 58:183-205.
61. Eigen M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13374-13376.
62. Graci J.D., Cameron C.E. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 2002, 298:175-180.
63. Graci J.D., Cameron C.E. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 2008, 3:553-566.
64. Orgel L.E. The maintenance of the accuracy of protein synthesis and its relevance to ageing. Proc. Natl. Acad. Sci. U.S.A. 1963, 49:517-521.
65. Orgel L.E. Ageing of clones of mammalian cells. Nature 1973, 243:441-445.
66. Manrubia S.C., et al. Pathways to extinction: beyond the error threshold. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2010, 365:1943-1952.
67. Cases-Gonzalez C., et al. Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J. Mol. Biol. 2008, 384:1120-1129.
68. Perales C., et al. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 2007, 369:985-1000.
69. Iranzo J., Manrubia S.C. Stochastic extinction of viral infectivity through the action of defectors. Europhys. Lett. 2009, 85:18001.
70. Mullins J.I., et al. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS ONE 2011, 6:e15135.
71. Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7289-7294.
72. Agudo R., et al. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 2010, 6:e1001072.
73. Ferrer-Orta C., et al. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 2010, 84:6188-6199.
74. Perales C., et al. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 2009, 5:e1000658.
75. Perales C., et al. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 2007, 369:985-1000.
76. Manrubia S.C. Modelling viral evolution and adaptation: challenges and rewards. Curr. Opin. Virol. 2012, 2:531-537.
77. Ojosnegros S., et al. Viral genome segmentation can result from a trade-off between genetic content and particle stability. PLoS Genet. 2011, 7:e1001344.
78. Iranzo J., Manrubia S.C. Evolutionary dynamics of genome segmentation in multipartite viruses. Proc. R. Soc. Lond. B 2012, 279:3812-3819.
79. Perales C., et al. Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J. Mol. Biol. 2011, 407:60-78.
80. Koelle K., et al. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 2006, 314:1898-1903.